Recent Updates
Recently added Catalysts

Rifaximin 550 milligrams

Phase 2

Alzheimer's Disease | Small molecule | Neurology |Bausch + Lomb Corporation|Last Updated: Dec 17, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment10
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03856359Trial of Rifaximin in Probable Alzheimer's DiseasePHASE2 COMPLETED 10Apr 9, 2019Nov 19, 2020Dec 17, 20211 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile
5 months

Collected at every visit and follow-up phone visits. A rare side effect of Rifaximin is diarrhea caused by clostridium difficile. This is a very serious form of diarrhea that can be fatal if not treated. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated.

Change in ADAS Cog 11 Scores
At baseline and at 3 months

Change in Alzheimer's Disease Assessment Scale - Cognition test with 11 tasks (ADAS Cog 11) scores following 3 months of oral Rifaximin. Scores range from minimum 0 - maximum 70. Higher scores mean worse outcome.

Secondary Endpoints
Change in Tolerability as Measured by Number of Adverse Events (AE).
Baseline, 3 months, 5 months
Change in Cognitive Performance on the Mini-Mental State Exam (MMSE)
Baseline, 3 months
Participants With Treatment Emergent Adverse Events as Reported by the Subject That Required a Change in Safety Measures
Safety will be measured through adverse events throughout study, at month 3 and by phone call at month 5 (2 months after treatment termination).
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
RifaximinEXPERIMENTALrifaximin 550 milligrams (mg) orally twice daily for 3 months
Interventions
NameTypeDescription
Rifaximin 550 milligrams (MG)DRUGRifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
Unlock Study Design Details
Eligibility Criteria
Age Range55 Years — 85 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * · Probable Alzheimer's Disease (National Institute of Neurological Disorders and Stroke (NINDS) criteria), mild to moderate severity * Ages 55-85; both genders * Mini Mental State Exam (MMSE) scores 10-23 * Willing and able to comply with all scheduled clinic visits. ...

Countries:United States
Unlock Eligibility Criteria